×
VYNE Therapeutics EBITDA 2016-2024 | VYNE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
VYNE Therapeutics ebitda from 2016 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
VYNE Therapeutics EBITDA 2016-2024 | VYNE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
VYNE Therapeutics ebitda from 2016 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$78.6B
Takeda Pharmaceutical (TAK)
$44.1B
Merck (MKKGY)
$21.2B
Astellas Pharma (ALPMY)
$20.4B
Sandoz Group AG (SDZNY)
$19.7B
United Therapeutics (UTHR)
$18B
Summit Therapeutics (SMMT)
$15.6B
Neurocrine Biosciences (NBIX)
$12.6B
Shionogi (SGIOY)
$12.5B
Catalent (CTLT)
$10.9B
Madrigal Pharmaceuticals (MDGL)
$7.7B
Jazz Pharmaceuticals (JAZZ)
$7.4B
Orion OYJ (ORINY)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.1B
Corcept Therapeutics (CORT)
$5.7B
Crinetics Pharmaceuticals (CRNX)
$4.8B
PTC Therapeutics (PTCT)
$3.3B
Dyne Therapeutics (DYN)
$2.9B
Catalyst Pharmaceuticals (CPRX)
$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.7B
Soleno Therapeutics (SLNO)
$2.5B
NewAmsterdam Pharma (NAMS)
$2B
Recursion Pharmaceuticals (RXRX)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
Harrow (HROW)
$1.8B
Ocular Therapeutix (OCUL)
$1.7B
Xencor (XNCR)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
ARS Pharmaceuticals (SPRY)
$1.6B